SCHEMBL1671304

SCHEMBL1671304

CCOc1cccc(Cl)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.49
BTK Q06187 1/20 0.45
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
GRM5 P41594 2/20 0.39
DRD4 P21917 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
NPC1 O15118 1/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38
CDK9 P50750 1/20 0.37
DYRK1A Q13627 1/20 0.37
DYRK2 Q92630 1/20 0.37
ADORA1 P30542 1/20 0.36
HTR7 P34969 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
NQO1 P15559 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30271358 1.00 MAPK8 (0.49) MAPK8BTKALDH1A1L3MBTL1GRM5
SCHEMBL9065338 0.85 MAPK8 (0.37) MAPK8BTKALDH1A1L3MBTL1GRM5
SCHEMBL2525163 0.84 MAPK8 (0.56) MAPK8BTKALDH1A1GRM5CYP3A4
SCHEMBL10910803 0.84 MCHR1 (0.42) MAPK8ALDH1A1L3MBTL1GRM5DRD4
Ammonia Solution, Strong SCHEMBL2186005 0.82 MCHR1 (0.41) MAPK8ALDH1A1L3MBTL1GRM5DRD4
SCHEMBL10911295 0.82 MCHR1 (0.44) ALDH1A1L3MBTL1CYP3A4TSHRNPC1
SCHEMBL27852278 0.81 MCHR1 (0.45) TSHRCDK9DYRK1ADYRK2HTR7
SCHEMBL7520131 0.80 MCHR1 (0.47) TSHRCDK9DYRK1ADYRK2HTR7
SCHEMBL27852180 0.80 MCHR1 (0.47) TSHRCDK9DYRK1ADYRK2HTR7
SCHEMBL9928722 0.79 MAPK8 (0.49) MAPK8BTKALDH1A1GRM5CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 EP disclosed
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
EP-4660182-A1 NAV1.7- AND/OR NAV1.8-INHIBITING ARYL PYRIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS Eurofarma Laboratórios S.A. (BR) 2025-12-10 EP disclosed
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2025-08-05 US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 US disclosed
US-12215093-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2025-02-04 US disclosed
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. 2025-01-30 US disclosed
US-4456605-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1984-06-26 US disclosed
EP-0102652-A1 Method for the preparation of pure 2-chloro-6-alkoxy-3-nitro-pyridines RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) 1984-03-14 EP disclosed
US-4402957-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1983-09-06 US disclosed
US-4360676-A 3,3,5-Trichloroglutaric acid imide CIBA-GEIGY CORPORATION (US) 1982-11-23 US disclosed
EP-0007696-B1 HETEROCYCLIC DERIVATIVES OF (4-(PIPERAZIN-1-YL-PHENYLOXYMETHYL)-1.3.-DIOXOLAN-2-YLMETHYL)-1H-IMIDAZOLES AND -1H-1.2.4-TRIAZOLES, THEIR PREPARATION AND USE AS FUNGICIDES AND BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1982-10-27 EP disclosed
US-4327216-A Process for producing 2,3,5,6-tetrachloropyridine and 3,5,6-trichloropyridin-2-ol CIBA-GEIGY CORPORATION (US) 1982-04-27 US disclosed
US-4287195-A USEFUL AS BACTERICIDES AND FUNGICIDES JANSSEN PHARMACEUTICA, N.V. (BE) 1981-09-01 US disclosed
EP-0030214-A2 Process for the preparation of 2,3,5,6-tetrachloropyridine and 3,5,6-trichloropyridin-2-ol CIBA-GEIGY AG (CH) 1981-06-10 EP disclosed
EP-0030215-A2 3,3,5-Trichloroglutarimide, process for its preparation and its use in the preparation of 2,3,5,6-tetrachloropyridine CIBA-GEIGY AG (CH) 1981-06-10 EP disclosed
EP-0007696-A1 Heterocyclic derivatives of (4-(piperazin-1-yl-phenyloxymethyl)-1.3.-dioxolan-2-ylmethyl)-1H-imidazoles and -1H-1.2.4-triazoles, their preparation and use as fungicides and bactericides JANSSEN PHARMACEUTICA N.V. (BE) 1980-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B MAPK8 2232/4885BTK 3132/4885ALDH1A1 2242/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B MAPK8 2232/4885BTK 3132/4885ALDH1A1 2242/4885
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR3 MAPK8 2031/4885BTK 3939/4885ALDH1A1 1523/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B MAPK8 2632/4885BTK 3378/4885ALDH1A1 1068/4885
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators HCRTR2, HCRTR1, OXTR MAPK8 3035/4885BTK 4064/4885ALDH1A1 3132/4885
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 MAPK8 2642/4885BTK 2596/4885ALDH1A1 1392/4885
US-12215093-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 MAPK8 2642/4885BTK 2596/4885ALDH1A1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.